Connect Biopharma Posts Q2 Revenue Drop

Connect Biopharma (NASDAQ:CNTB), a biotechnology company developing therapies for inflammatory diseases, released its second quarter 2025 earnings on August 13, 2025. The main highlight was a substantial drop in GAAP revenue, from $24.1 million in Q2 2024 to just $48,000 in Q2 2025. Reported GAAP earnings per share (EPS) were $(0.23) for Q2 2025. Research and development spending (GAAP) increased sharply, reflecting new and ongoing clinical trials, while cash reserves declined but remained adequate. Source: Analyst estimates for the quarter provided by FactSet. Connect Biopharma works to develop new therapies targeting immune and inflammatory diseases. Its primary focus is on rademikibart, a monoclonal antibody product designed to treat asthma and chronic obstructive pulmonary disease (COPD). The company is in a pre-commercial phase, meaning it does not yet sell products and relies on licensing revenue and existing cash to fund research and development. Most of its near-term success hinges on progressing clinical trials and achieving regulatory approvals for rademikibart and other pipeline candidates.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool